Bo Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Song has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Bo Wang
9 shared publicationsYing Lu
9 shared publicationsJie Shen
7 shared publicationsLu Wang
7 shared publicationsJun Mao
5 shared publicationsLihui Yu
5 shared publications
Latest Publications
- RetractionOpen Access
- 9 November 2022
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 30, 378
Retraction Notice to: A Novel Mechanism of Doxorubicin Resistance and Tumorigenesis Mediated by MicroRNA-501-5p-Suppressed BLID
- 9 November 2022
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 30, 378
RetractionOpen AccessRetraction Notice to: A Novel Mechanism of Doxorubicin Resistance and Tumorigenesis Mediated by MicroRNA-501-5p-Suppressed BLID
- RetractionOpen Access
- 5 November 2022
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 30, 353
Retraction Notice to: MicroRNA-140 Inhibits the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer
- 5 November 2022
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 30, 353
RetractionOpen AccessRetraction Notice to: MicroRNA-140 Inhibits the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer
- RetractionOpen Access
- 15 February 2021
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 12 (1) , 1
Retraction Note: microRNA-140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5
This arcticle has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13287-016-0438-5.
- 15 February 2021
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 12 (1) , 1
RetractionOpen AccessRetraction Note: microRNA-140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5
This arcticle has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13287-016-0438-5.
- Open Access
- 13 June 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-14
PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway
Background: Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, has been reported to exert its tumor suppressive function via modulation of PTEN expression in many malignancies, including breast cancer (BC). However, whether the PTENP1/miR-20a/PTEN axis exists and how it functions in BC progression remains elusive. Methods: The levels of PTENP1, PTEN and miR-20a were measured by qRT-PCR. Furthermore, the breast cancer cells proliferation was further measured by CCK8 assay, colony formation assays, EDU and Ki67 staining. The migratory and invasive ability was determined by transwell assay. Flow cytometry, JC-1 and TUNEL assays were conducted to show the occurrence of apoptosis. Xenograft model was used to show the tumorigenesis of breast cancer cells. Results: We analyzed PTENP1 and PTEN levels in clinical BC samples and cell lines, and found that PTENP1 and PTEN were confirmed and closely correlated with the malignancy of BC cell lines and poor clinical prognosis. Moreover, alteration of PTENP1 affects BC cell proliferation, invasion, tumorigenesis and chemoresistance to adriamycin (ADR). Bioinformatic analysis and dual-luciferase reporter gene assay predicted that PTENP1 was a direct target of miR-20a, which was clarified an alternative effect on BC aggressiveness phenotype. In addition, PTENP1 functioned as an endogenous sponge of miR-20a to regulate PTEN expression, which mediated BC cells proliferation, invasion and drug resistance via activation the phosphatidylinositol-3 kinase (PI3K)/AKT pathway. PI3K inhibitor LY294002 or siAkt also prevented BC cells progression. Conclusion: Collectively, these data indicated that PTENP1/miR-20a/PTEN axis involved in the malignant behaviors of BC cells, illuminating the possible mechanism mediated by PTEN via PI3K/Akt pathway. Targeting PTENP1/miR-20a/PTEN may provide a potential diagnosis and treatment strategy for BC.
- 13 June 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-14
Open AccessPTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway
Background: Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, has been reported to exert its tumor suppressive function via modulation of PTEN expression in many malignancies, including breast cancer (BC). However, whether the PTENP1/miR-20a/PTEN axis exists and how it functions in BC progression remains elusive. Methods: The levels of PTENP1, PTEN and miR-20a were measured by qRT-PCR. Furthermore, the breast cancer cells proliferation was further measured by CCK8 assay, colony formation assays, EDU and Ki67 staining. The migratory and invasive ability was determined by transwell assay. Flow cytometry, JC-1 and TUNEL assays were conducted to show the occurrence of apoptosis. Xenograft model was used to show the tumorigenesis of breast cancer cells. Results: We analyzed PTENP1 and PTEN levels in clinical BC samples and cell lines, and found that PTENP1 and PTEN were confirmed and closely correlated with the malignancy of BC cell lines and poor clinical prognosis. Moreover, alteration of PTENP1 affects BC cell proliferation, invasion, tumorigenesis and chemoresistance to adriamycin (ADR). Bioinformatic analysis and dual-luciferase reporter gene assay predicted that PTENP1 was a direct target of miR-20a, which was clarified an alternative effect on BC aggressiveness phenotype. In addition, PTENP1 functioned as an endogenous sponge of miR-20a to regulate PTEN expression, which mediated BC cells proliferation, invasion and drug resistance via activation the phosphatidylinositol-3 kinase (PI3K)/AKT pathway. PI3K inhibitor LY294002 or siAkt also prevented BC cells progression. Conclusion: Collectively, these data indicated that PTENP1/miR-20a/PTEN axis involved in the malignant behaviors of BC cells, illuminating the possible mechanism mediated by PTEN via PI3K/Akt pathway. Targeting PTENP1/miR-20a/PTEN may provide a potential diagnosis and treatment strategy for BC.
- RetractedOpen Access
- 1 September 2018
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 12, 578-590
RETRACTED: A Novel Mechanism of Doxorubicin Resistance and Tumorigenesis Mediated by MicroRNA-501-5p-Suppressed BLID
- 1 September 2018
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 12, 578-590
RetractedOpen AccessRETRACTED: A Novel Mechanism of Doxorubicin Resistance and Tumorigenesis Mediated by MicroRNA-501-5p-Suppressed BLID
- 1 April 2018
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 285, 85-95
miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD
- 1 April 2018
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 285, 85-95
miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD
- RetractedOpen Access
- 1 March 2018
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 10, 426-437
RETRACTED: MicroRNA-140 Inhibits the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer
- 1 March 2018
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 10, 426-437
RetractedOpen AccessRETRACTED: MicroRNA-140 Inhibits the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer
- 1 November 2017
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 277, 33-42
miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation
- 1 November 2017
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 277, 33-42
miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation